New ASH25 Insights on Bleeding Risk in Cancer-Associated VTE
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”New Insights on Bleeding Risk During Extended Anticoagulation in Cancer-Associated VTE
Presented at ASH25 and published in Lancet Haematology, this post-hoc analysis of the API-CAT trial, led by Prof. Isabelle Mahé, identifies key predictors of clinically relevant bleeding during extended apixaban therapy in patients with active cancer.
Key Predictors of Higher Bleeding Risk
• Anemia and/or thrombocytopenia (HR 1.93)
• Age ≥75 years (HR 1.51)
• Index pulmonary embolism (HR 1.47)
• Male sex (HR 1.38)
These predictors were consistent across cancer types and also aligned with predictors of major bleeding. See manuscript here.”
Title: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Prof Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Prof Charles-Marc Samama, Hélène Helfer, Prof Grigoris Gerotziafas, Prof Silvy Laporte, Prof Eric Vicaut, Prof Patrick Mismetti
Stay updated with Hemostasis Today.
-
Jul 27, 2026, 13:27Antonio Lauletta: Distinguishing Sporadic and ICI-Related MG-Myositis Overlap
-
Jul 27, 2026, 13:15Satyam Arora: Welcoming the New ISBT Board and Looking Ahead
-
Jul 27, 2026, 13:03Jeff Parke: Why We Are Losing Viable Kidneys in Transit
-
Jul 27, 2026, 12:58George Hajishengallis: A New Era in Periodontal Disease Treatment
-
Jul 27, 2026, 12:54Elena Masselli: Can Statins Enhance Peginterferon Therapy in MPNs?
-
Jul 27, 2026, 12:32Sonia Elena Popovici: Redefining Hemorrhagic Shock Through Cellular and Molecular Insights
-
Jul 27, 2026, 12:24Abdul Mannan: Why Quantitative FXIII Testing Matters
-
Jul 27, 2026, 12:13Ney Carter Borges: Biomechanics of Plaque Erosion in ACS
-
Jul 27, 2026, 12:05Irma Bagdoniene: The Silent Progression of Coronary Artery Disease